Clinical Trials
Riverside is here for you during the COVID-19 outbreak.

For more information, please click here.

A011801

A011801  The COMPASSHER2 Residual Disease Trial A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib

A011801: The COMPASSHER2 Residual Disease Trial A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib

 

This study is being done to answer the following question: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone in preventing breast cancer from returning? We are doing this study because we want to find out if this approach is better or worse than the usual approach for breast cancer.

Principal Investigator

William MacLaughlin, MD

Contact

Ora Mae Jackson, RN, OCN
757-534-5565
[email protected]

Locations

All Peninsula Cancer Institute and Cancer Specialists of Tidewater sites

Status

Recruiting

Category

Oncology

Study #

NCT04457596